不同类型干细胞在缺血性心脏病治疗及转化中的应用进展

Progress in the clinical application and transformation of the different types of stem cells in the treatment of ischemic heart disease

充血性心脏衰竭(CHF)继发于慢性冠状动脉疾病,是导致心血管疾病死亡率升高的主要原因之一,其患病率并没有随着医疗设备发展和医学技术进步而下降。目前干细胞疗法是一个有良好前景的治疗方法,该疗法能够改善心功化,进而阻止CHF形成。目前,从骨髓和心脏分离的祖细胞疗效在临床前大动物模型上已被评估。一些临床试验使用自体和同种异体干细胞和祖细胞已经证明他们运用于人体是安全的。本文将讨论三种再生能力强的成体干细胞:骨髓间充质干细胞,心脏肌球衍生细胞和心脏干细胞的最新研究进展。

Congestive heart failure(CHF) secondary to chronic coronary artery disease is one of the leading causes of cardiovascular disease mortality. Its prevalence has not declined with the development of medical equipment and medical technology. For now, cell based therapies generating new cardiomyocytes and vessels have emerged as a promising treatment to reverse functional deterioration and prevent the progression of CHF. Functional efficacy of progenitor cells isolated from the bone marrow and the heart have been evaluated in preclinical large animal models. Several clinical trials have used autologous and allogeneic stem cells, and have been shown to be safe in humans. In this paper,we will discuss the latest research progress of three adult stem cells that have shown particularly promising regenerative ability: bone marrow mesenchymal stem cell, cardiac myocyte derived cell and cardiac stem cell.